Technology Bundle ID
TAB-2639

Antigen-capture Electrochemiluminescent Assay for Determining Rabies Vaccine Potency

Linked ID
E-180-2013-0
Co-Inventors
Charles Rupprecht (CDC)
Development Status
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
ICs
CDC
CDC researchers developed a more efficient method of assessing rabies vaccine potency using an antigen-capture electrochemiluminescent (ECL) assay. This assay utilizes SULFO-NHS-Ester labeled murine monoclonal antibodies to quantify glycoprotein concentration, which is an indicator of vaccine potency. Currently, the potency of rabies vaccines is determined by the effective-dose (ED50) mouse study evaluation method, which is more than 50 years old. The labor-intensive ED50 evaluation method has high operating costs, extensive biosafety requirements, and requires the sacrifice of a large number of animals. CDC researchers have addressed these issues by developing a competitive in vitro antigen-capture assay that is rapid, highly robust, reproducible, flexible and much less expensive to implement than the traditional ED50-mouse study evaluation.
Commercial Applications
  • Rabies vaccine design and development
  • Vaccine quality control and quality assurance testing
  • In vitro assay for rabies virus glycoprotein
Competitive Advantages
  • Efficient vaccine evaluation
  • Highly robust, reproducible and flexible
  • Easily standardized for consistent, universal usage and assurance of batch-to-batch vaccine homogeneity
  • In vitro assay may replace the 50 year old ED50 mouse procedure

Request More Info

Licensing Contact: